case_images: PMC10748863_01
case_images: MRI image of the prostate lesion on axial T2-weighted imaging (green arrows indicate the lesion).
case_images: RRU-15-571-g0001.jpg
case_images: PMC10748863_01_RRU-15-571-g0001.jpg
case_images: f0001
case_images: PIRADS 4 lesion in the anterior zone of the prostate (see Figure 1). PSMA PET identified focal and markedly increased tracer uptake in the anterior zone of the prostate concordant with the MRI lesion (see Figure 2).
case_images: PSMA PET image of the prostate lesion.
case_images: RRU-15-571-g0002.jpg
case_images: PMC10748863_01_RRU-15-571-g0002.jpg
case_images: f0002
case_images: PIRADS 4 lesion in the anterior zone of the prostate (see Figure 1). PSMA PET identified focal and markedly increased tracer uptake in the anterior zone of the prostate concordant with the MRI lesion (see Figure 2).
case_images: Schematic of the prostate lesion (red shading highlights the location of the lesion within the prostate gland).
case_images: RRU-15-571-g0003.jpg
case_images: PMC10748863_01_RRU-15-571-g0003.jpg
case_images: f0003
case_images: Pathology demonstrated Gleason 4+5=9 adenocarcinoma with focal cribriform architecture, 0.6mm of extracapsular extension at the apex anteriorly, and clear margins, stage pT3a N0 M0 (see Figure 3).
case_images: Treatment timeline.
case_images: RRU-15-571-g0004.jpg
case_images: PMC10748863_01_RRU-15-571-g0004.jpg
case_images: f0004
case_images: PALB2 and TP53, was performed in the context of the high grade disease at a young age and did not identify a heritable cause. Please see Figure 4 for a treatment timeline schematic.